

# EUROPEAN FORMAT CURRICULUM VITAE



## PERSONAL INFORMATIONS

Name AURILIO GAETANO  
Address VIA EUGENIO VILLORESI, 18, 20143, MILAN, ITALY  
Fax +390294379234  
E-mail [gaetano.aurilio@ieo.it](mailto:gaetano.aurilio@ieo.it)  
Citizenship Italian  
Date of Birth MARCH 17 1977

## PROFESSIONAL EXPERIENCES

Employer European Institute of Oncology, Milan, Italy, Division of Urogenital and Head and Neck Cancer, head Dr. F. Nolè.  
10/31/2018-current Scientific National Abilitation for Associate Professor (MED 06/D3 sector: Blood diseases, Oncology and Rheumatology).  
5/2017 - current Medical Doctor.  
11/2011 - 4/2017 Physician Assistant at the European Institute of Oncology, Milan, Italy, Division of Urogenital and Head and Neck Cancer, head Dr. F. Nolè.  
11/2008 - 10/2011 Fellow with grant at the European Institute of Oncology, Milan, Italy, Medical Care Unit, head Dr. F. Nolè. Project work: "Prognostic and predictive role of circulating tumor cells in breast cancer".  
2004-2007 Fellowship with grant in Medical Oncology at the Second University of Naples, Naples, Italy. Mentor: Prof. Fortunato Ciardiello.  
1999-2003 Internship as a medical student at the Division of Medical Oncology, "F. Magrassi & A. Lanzara" Department of Clinical and Experimental Medicine, Second University of Naples, Naples. Mentor: Prof. Giuseppe Catalano.

## EDUCATION

ASCO Annual Meeting 2012 Winner of ASCO Merit Award 2012 by ASCO Conquer Cancer Foundation Merit Award. Project work: "A meta-analysis of receptor status discordance between primary breast cancer and metastases". Selected for Poster presentation at the 2012, June 2 2012.  
ESO-ESMO Masterclass 2012 Selected for 11th ESO-ESMO Masterclass in Clinical Oncology, Ermatingen, Switzerland.  
1/2011 Ph.D. Ph.D. in Medical and Surgical Oncology and Clinical Immunology, Second University of Naples, Italy. Title of thesis: "Immunomagnetic amount of circulating tumor cells as prognostic and predictive factor in hormone-refractory prostate cancer".

2010 SABCS	Poster presentation at the 2010 San Antonio Breast Cancer Symposium, San Antonio, Texas, USA. Project work: "Is bone biopsy of metastatic sites useful in advanced breast cancer management?"
Research Grant 2009	"Floriana Andolfi Diomelli award" for research in breast cancer, conferred by Prof. U. Veronesi, European Institute of Oncology, Milan, Italy.
2-10/2008 Clinical fellow	Clinical fellow at the Gastrointestinal Tumors and phase I Unit coordinated by Dr. Josep Tabernero (tutor), Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain, head Prof. Josè Baselga. Study project: "Learning the methodology of the phase I trials".
Erasmus 2008	Admitted to Erasmus project at the Second University of Naples, Naples, Italy (Ref. n. 80, March 25 2008).
Research Grant 12/2007	Grant for research in Medical Oncology 2007, conferred in Capua by the scientific committee of "Ferdinando Palasciano" Association, for scientific merit achieved with competence and dedication to the study.
11/2007 - 1/2011 Ph.D. Program	Postdoctoral Fellowship Research Program in Medical and Surgical Oncology and Clinical Immunology, Second University of Naples, Naples, 23° cycle.
2007	European Board in Medical Oncology.
2004-2007 Fellowship in Medical Oncology	Fellowship in Medical Oncology at the Second University of Naples, Italy. Title of thesis: "Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer, phase II study"; final score 50/50 cum laude.
2003	European Board in Internal Medicine, final score 88/90.
1996 - 2003	Medical School at the Second University of Naples, Italy. Degree in Medicine and Surgery at the Second University of Naples, final score 108/110. Title of thesis: "Adjuvant chemotherapy with epirubicin, etoposide, 5fluorouracil and folinic acid in gastric cancer patients: phase III trial, preliminary analysis".
1996	Baccalaureate at the Garofano Scientific High School, Capua, Italy, final score 58/60.

**TECHNICAL SKILLS AND COMPETENCES:**

MANAGEMENT OF PATIENTS WITH CANCER, WITH SPECIAL REFERENCES TO GENITOURINARY MALIGNANCIES AND BREAST CANCER. DATA MANAGING AND CO-INVESTIGATOR IN SEVERAL ON-GOING CLINICAL TRIALS, FROM STUDY DESIGN TO WRITING OF MANUSCRIPTS. MEMBER OF MULTIDISCIPLINARY INSTITUTIONAL TASK FORCE. CANCER CARE AND RESEARCH WITH GOOD CLINICAL PRACTICE TRAINING (LAST ICH GOOD CLINICAL PRACTICE TRAINING E6 R2 ON MAY 16 2018)

MOTHER-TONGUE	ITALIAN LANGUAGE
Other languages	ENGLISH
Reading level	Good
Writing level	Good
Oral expression	Good

**MEMBERSHIP**

2008 – current	ESMO, European Society for Medical Oncology
2008 – current	AIOM, Italian Society for Medical Oncology
2006 - current	GOIM, Oncology Group of South Italy

## PUBLICATIONS:

1. Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study. Carlomagno C, Orditura M, Pepe S, De Vita F, Romano C, Ciardiello F, Ferrara C, Martinelli E, Bianco R, Aurilio G, D'Agostino D, Tortora G, Catalano G, De Placido S. *American Journal Clinical Oncology* 2006 Feb; 29(1):85-9.
2. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. Orditura M, Martinelli E, Galizia G, Carlomagno C, Aurilio G, Vecchione L, Lieto E, De Placido S, Catalano G, Ciardiello F, De Vita F. *Ann Oncol.* 2006 Oct; 17(10):1529-32.
3. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. F. De Vita , F. Giuliani, G. Galizia, C. Belli, G. Aurilio, G. Santabarbara, F. Ciardiello, G. Catalano & M. Orditura. *Ann Oncol.* 2007 Jun; 18 Suppl 6:vi120-3. Review.
4. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and P53 overexpression in endocrine positive primary breast cancer. F. Iovino, F. Ferraraccio, M. Orditura, G. Antonio, F. Morgillo, T. Cascone, MR. Diadema, G. Aurilio, G. Santabarbara, R. Ruggiero, C. Belli, E. Irlandese, M. Fasano, F. Ciardiello, E. Procaccini, F. Lo Schiavo, G. Catalano, F. De Vita. *Cancer Investigation* 2008 Apr-May; 26(3):250-5.
5. Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study. Orditura M, Galizia G, Napolitano V, Martinelli E, Pacelli R, Lieto E, Aurilio G, Vecchione L, Morgillo F, Catalano G, Ciardiello F, Del Genio A, Di Martino N, De Vita F. *Cancer Invest.* 2010 Oct;28(8):820-7.
6. A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC). Aurilio G, Ricci V, De Vita F, Fasano M, Fazio N, Orditura M, Funicelli L, De Luca G, Iasevoli D, Iovino F, Ciardiello F, Conzo G, Nolè F, Lamendola M. *Ecancermedicalscience.* 2010;4:197.
7. Should liver metastases of breast cancer be biopsied to improve treatment choice? Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensch N, Aurilio G, Locatelli M, Pruneri G, Giudici S, Bellomi M, Della Vigna P, Monfardini L, Orsi F, Nolè F, Munzone E, Goldhirsch A. *Ann Oncol.* 2011 Feb 22.
8. Successful treatment with GEMOX in patient with metastatic pancreatic adenosquamous carcinoma. Aurilio G, Macarulla T, Ramos JF, Fazio N, Nolè F, Iglesias C. *Tumori.* 2011 Mar-Apr;97(2):239-42.
9. Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E; ISA Co-Authors, Airoldi M, Amoroso D, Ardizzioia A, Aurilio G et al. *Lung Cancer.* 2011 Jul;73(1):78-88.
10. Use of metronomic chemotherapy in oncology: results from a national Italian survey. Collovà E, Sebastiani F, De Matteis E, Generali D, Aurilio G, Boccardo F, Crispino S, Cruciani G. *Tumori.* 2011 Jul-Aug;97(4):454-8.
11. Prognostic value of circulating tumor cells in primary and metastatic breast cancer. Aurilio G, Sciandivasci A, Munzone E et al. *Expert Rev Anticancer Ther.* 2012 Feb;12(2):203-14.
12. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report. Aurilio G, Munzone E, Botteri E, Sciandivasci A, Adamoli L, Minchella I, Esposito A, Cullurà D, Curigliano G, Colleoni M, Goldhirsch A, Nolè F. *Breast J.* 2012 Sep;18(5):470-4.
13. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensch N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F. *Clin Breast Cancer.* 2012 Oct;12(5):340-6.

14. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, Disalvatore D, Pruneri G, Munzone E, Della Vigna P, Renne G, Bellomi M, Curigliano G, Goldhirsch A, Nolè F. *Acta Oncol.* 2013 Jan 17.
15. Role of breast surgery in T1-3 breast cancer patients with synchronous bone metastases. Botteri E, Munzone E, Intra M, Bagnardi V, Rotmensz N, Bazolli B, Montanari B, Aurilio G, Sciandivasci A, Esposito A, Pagani G, Adamoli L, Viale G, Nolè F, Goldhirsch A. *Breast Cancer Res Treat.* 2013 Feb 15.
16. Outcome and clinico-biological characteristics of advanced breast cancer patients with surgically resected brain metastases: a multidisciplinary approach. Munzone E, Casali C, Aurilio G, Botteri E, Perin A, Pelicci G, Brescia P, Sciandivasci A, Adamoli L, Viale G, Dimeco F. *Ecancermedicalscience.* 2013 Apr 18;7:309.
17. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. Rossi V, Nolè F, Redana S, Adamoli L, Martinello R, Aurilio G, Verri E, Sapino A, Viale G, Aglietta M, Montemurro F. *Breast.* 2013 Nov 7.
18. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F, Goldhirsch A, Nolè F. *Eur J Cancer.* 2013 Nov 21.
19. Reply to letter by Ieni et al. Aurilio G, Nolè F, Viale G, Pruneri G. *Eur J Cancer.* 2014 Mar;50(5):1038-9.
20. Ct-guided bone biopsy in cancer patients with suspected bone metastases: retrospective review of 308 procedures. Monfardini L, Preda L, Aurilio G, Rizzo S, Bagnardi V, Renne G, Maccagnoni S, Vigna PD, Davide D, Bellomi M. *Radiol Med.* 2014 Apr 4.
21. Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series. Aurilio G, Graffeo R, Bagnardi V, Nolè F, Adamoli L, Pagani O, Gallerani E, Ferrari B, Pruneri G, Goldhirsch A. *International Journal of Clinical Oncology* 2014.
22. Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis. Collovà E, Ferzi A, Scandurra G, Aurilio G, Torri V, Porcu L, Sanò MV, Taibi E, Foglietta J, Generali D, Andreis D, Dazzani MC, Bramati A, Marcon I, Atzori F, Cinieri S, Tondulli L, Grasso D, Nolè F, Petrella MC, Gori S, La Verde N. *Tumori.* 2014 Jul-Aug;100(4):426-31.
23. Does Immediate Breast Reconstruction after Mastectomy and Neoadjuvant Chemotherapy Influence the Outcome of Patients with Non-endocrine Responsive Breast Cancer? Aurilio G, Bagnardi V, Graffeo R, Nolè F, Petit JY, Locatelli M, Martella S, Iera M, Rey P, Curigliano G, Rotmensz N, Munzone E, Goldhirsch A. *Anticancer Res.* 2014 Nov;34(11):6677-83.
24. Sunitinib two weeks on, one off: strengths and weaknesses. Iacovelli R, Verri E, Cossu Rocca M, Aurilio G, Cullurà D, Nolè F. *Ann Oncol.* 2015 Apr 6.
25. Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study. Aurilio G, Bagnardi V, Nolè F, Pruneri G, Graffeo R, Petit JY, Cullurà D, Martella S, Locatelli M, Iera M, Rey P, Curigliano G, Rotmensz N, Munzone E, Goldhirsch A. *Clin Breast Cancer.* 2015 Mar 24.
26. Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian Association of Medical Oncology. Aurilio G, Gori S, Nolè F, Pruneri G, Coati F, Torri V, Lunardi G, Atzori F, La Verde N, Banna GL, Rossi A, Del Mastro L, Di Fabio F, Marcon I, Gebbia V, Loupakis F, Orlando L, Ciuffreda L, Amadio P, Luppi G, Redana S, Filippelli G, Gentile A, Collovà E. *Tumori.* 2016 Jan-Feb;102(1):108-13.

27. The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. Iacovelli R, Verri E, Cossu Rocca M, Aurilio G, Cullurà D, De Cobelli O, Nolè F. *Eur J Cancer*. 2015 Sep;51(14):1970-7. Review.
28. Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. Iacovelli R, Nolè F, Verri E, Renne G, Paglino C, Santoni M, Cossu Rocca M, Giglione P, Aurilio G, Cullurà D, Cascinu S, Porta C. *Target Oncol*. 2016 Apr;11(2):143-8. Review.
29. Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. Iacovelli R, Verri E, Cossu Rocca M, Aurilio G, Cullurà D, Santoni M, de Cobelli O, Nolè F. *Crit Rev Oncol Hematol*. 2016 Mar; 99:324-31. Review.
30. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. Aurilio G, Sandri MT, Pruneri G, Zorzino L, Botteri E, Munzone E, Adamoli L, Facchi G, Cullurà D, Verri E, Rocca MC, Zurrada S, Iacovelli R, Nolè F. *Future Oncol*. 2016 Sep;12(17):2001-8.
31. Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors. Iacovelli R, Verri E, Cossu Rocca M, Aurilio G, Cullurà D, de Cobelli O, Nolè F. *Anticancer Drugs*. 2016 Oct 26.
32. Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report. Fasano M, Fabozzi A, Giordano G, Venturini F, Aurilio G, Cantile F, Fabozzi T, Ricci V, Santabarbara G, Morgillo F, Ciardiello F, De Vita F. *Oncol Lett*. 2017 Feb;13(2):979-983.

I grant permission for my personal information to be used, fef. Law 196/03.

UPDATED: January 22, 2019

Gaetano Aurilio